Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARQT Arcutis Biotherapeutics Inc.

Post-Mkt 09-08 17:25:27 EDT

24.39

+0.49

+2.05%

盘后24.39

+0.000.00%

17:24 EDT

High25.13	Low24.09	Vol4.53M
Open24.84	D1 Closing23.90	Amplitude4.35%
Mkt Cap3.05B	Tradable Cap2.71B	Total Shares125.07M
T/O111.24M	T/O Rate4.07%	Tradable Shares111.18M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ARQT","market":"US","secType":"STK","nameCN":"Arcutis Biotherapeutics Inc.","latestPrice":24.39,"timestamp":1788897600000,"preClose":23.9,"halted":0,"volume":4530222,"hourTrading":{"tag":"盘后","latestPrice":24.39,"preClose":24.39,"latestTime":"17:24 EDT","volume":70698,"amount":1724324.22,"timestamp":1788902642446,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02050209205020929,"floatShares":111176161,"shares":125073249,"eps":0.215414,"marketStatus":"Post-Mkt","change":0.49,"latestTime":"09-08 17:25:27 EDT","open":24.84,"high":25.13,"low":24.09,"amount":111240321.515298,"amplitude":0.043515,"askPrice":24.87,"askSize":80,"bidPrice":23.91,"bidSize":83,"shortable":3,"etf":0,"ttmEps":0.215414,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788912000000},"marketStatusCode":4,"adr":0,"listingDate":1580446800000,"exchange":"NASDAQ","adjPreClose":23.9,"preHourTrading":{"tag":"盘前","latestPrice":24.87,"preClose":23.9,"latestTime":"09:29 EDT","volume":2053,"amount":50456.10881,"timestamp":1788874199510,"change":0.97,"changeRate":0.040586,"amplitude":0.041862},"postHourTrading":{"tag":"盘后","latestPrice":24.39,"preClose":24.39,"latestTime":"17:24 EDT","volume":70698,"amount":1724324.22,"timestamp":1788902642446,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":3.090404,"impliedVol":0.7149,"impliedVolPercentile":0.8127},"requestUrl":"/m/hq/s/ARQT/wiki","defaultTab":"wiki","newsList":[{"id":"1115350276","title":"S&P 500 to Add Bloom Energy, Illumina and Everpure in September Rebalance","url":"https://stock-news.laohu8.com/highlight/detail?id=1115350276","media":"Tiger Newspress","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115350276?lang=en_us&edition=fundamental","pubTime":"2026-09-05 07:27","pubTimestamp":1788564468,"startTime":"0","endTime":"0","summary":"S&P Dow Jones Indices will add $Bloom Energy(BE)$, $Everpure(P)$ and $Illumina(ILMN)$ to the S&P 500 as part of its quarterly index rebalance, with the changes taking effect before the U.S. market...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CL","SNDQ","AXTQ","SNDK","PALU","SNXX","P","AXTI","PALD","SNDC","HRI","AGNC","AXTX","DK","ANEL","PUL","TAP","BEG","SAM","SNDG","PANW","ARQT","TTDU","ANET","CPRI","ILMN","SNDU","DLLL","BE","TTD","CORT","ATRC","AXTL","BEC","BEZ","HUBS","HONA","BLDR","EAT","AXTC","AXTU","DELL","BEX","PANG","SPG","NKE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665142359","title":"Arcutis Biotherapeutics Grants 57,000 RSUs to 11 New Hires Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2665142359","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665142359?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:00","pubTimestamp":1788552013,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics grants 57,000 RSUs to 11 new hires under inducement planArcutis Biotherapeutics granted 57,000 restricted stock units to 11 newly hired employees under its 2022 Inducement Plan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDLc1Q2Ky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","IE00BKPKM429.USD","LU2095319765.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","ARQT","BCDF","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","LU2210149790.SGD","NDAQ","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","SG9999014039.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665835915","title":"Press Release: Arcutis Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665835915","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665835915?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:00","pubTimestamp":1788552000,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQJ","TECS","QLD","QQQM","QQQ","BK4139","FTEC","QQQA","QQQY","SQQQ","QDTE",".IXIC","MNQmain","QQQE","JEPQ","NVIW.SI","03086","ONEQ","ARQT","TQQQ","GPIQ","PSQ","QYLG","NDX","TQQY","QID","IYW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663015037","title":"Arcutis Director Terrie Curran Disposes of Common Shares Worth $279,129.66","url":"https://stock-news.laohu8.com/highlight/detail?id=2663015037","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663015037?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:40","pubTimestamp":1787953242,"startTime":"0","endTime":"0","summary":"Arcutis director Terrie Curran disposes of common shares worth $279,129.66Arcutis Biotherapeutics director Terrie Curran exercised stock options on Aug. 27, 2026, acquiring 38,200 common shares at USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL9g5k3P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Arcutis Director Terrie Curran Disposes of Common Shares Worth $279,129.66","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662121081","title":"Is Arcutis Biotherapeutics (ARQT) Stock Too Rich To Stay Reasonable?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662121081","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662121081?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:31","pubTimestamp":1787844711,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics stock has produced very strong 3 year gains, yet the current market multiples screen it as overvalued and the broader valuation checks point to a mixed picture rather than a clear bargain. For investors, that raises the question of how much of Arcutis Biotherapeutics' recent success is already reflected in the US$25.14 share price.\n\nOver the past 3 years Arcutis Biotherapeutics has returned about 181.5%, which puts recent weakness into context and suggests expectations...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/is-arcutis-biotherapeutics-arqt-stock-too-rich-to-stay-reaso","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/is-arcutis-biotherapeutics-arqt-stock-too-rich-to-stay-reaso","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TSPA","ARQT","BK4139","TACU","CDIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662400200","title":"Insider Move at Arcutis Biotherapeutics Sends Strong Signal to Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662400200","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662400200?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:11","pubTimestamp":1787623904,"startTime":"0","endTime":"0","summary":"New insider activity at Arcutis Biotherapeutics ( ($ARQT) ) has taken place on August 24, 2026. Director Terrie Curran has recently sold 1,072 shar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-move-at-arcutis-biotherapeutics-sends-strong-signal-to-investors-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-move-at-arcutis-biotherapeutics-sends-strong-signal-to-investors-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4211","ISBC","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662320659","title":"Arcutis Biotherapeutics Director Terrie Curran Disposes of 1,072 Common Shares Worth $27,927.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2662320659","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662320659?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:20","pubTimestamp":1787602815,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics director Terrie Curran disposes of 1,072 common shares worth $27,927.31Arcutis Biotherapeutics director Terrie Curran exercised stock options for 1,072 common shares at USD 7.5","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL4DfnCn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Arcutis Biotherapeutics Director Terrie Curran Disposes of 1,072 Common Shares Worth $27,927.31","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662205703","title":"Oruka Therapeutics Names Todd Edwards Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662205703","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662205703?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:01","pubTimestamp":1787601676,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics names Todd Edwards chief commercial officerOruka Therapeutics named Todd Edwards chief commercial officer, effective Aug. 24, 2026.Edwards joins from Arcutis Biotherapeutics, where ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL6VDQwY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","XLV","AGNG","LU2347655156.SGD","PJP","LU1496350502.SGD","IE00B2B36J28.USD","IE00B3PB1722.GBP","LU0395794307.EUR","LU2357627491.SGD","JDOC","LU1718418525.SGD","BCDF","LU2210149790.SGD","IXJ","LU0689626769.HKD","VHT","LU0965508806.USD","LU0098860793.USD","LU1934455277.USD","IYH","LU0456855351.SGD","TRUH","ABBV","LU0820561909.HKD","FHLC","ORKA","LU1551013342.USD","LU1923622614.USD","PPH","LU1057294990.SGD","IE00BN0W2W23.USD","INCY","LU0211327993.USD","ARQT","GLAM","NDAQ","LU0124676726.USD","LU0738911758.USD","LU0949170772.SGD","SG9999015945.SGD","LU1291159041.SGD","IDNA","LU2210150020.SGD","RXL","MEDX","SG9999014021.USD","FTXH","LU2125909247.SGD","LU2129689431.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661215369","title":"Top Arcutis Executive Makes Notable Move With Latest Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2661215369","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661215369?lang=en_us&edition=fundamental","pubTime":"2026-08-22 10:09","pubTimestamp":1787364542,"startTime":"0","endTime":"0","summary":"New insider activity at Arcutis Biotherapeutics ( ($ARQT) ) has taken place on August 21, 2026. Patrick Burnett, EVP and Chief Medical Officer at A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-arcutis-executive-makes-notable-move-with-latest-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-arcutis-executive-makes-notable-move-with-latest-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661291076","title":"Arcutis-Backed Phase 3 ZORYVE Foam Study Targets Growth in Seborrheic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2661291076","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661291076?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:33","pubTimestamp":1787330020,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc ($ARQT) announced an update on their ongoing clinical study. The phase 3 study “A Phase 3 Multicenter, Randomized, Para...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arcutis-backed-phase-3-zoryve-foam-study-targets-growth-in-seborrheic-dermatitis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arcutis-backed-phase-3-zoryve-foam-study-targets-growth-in-seborrheic-dermatitis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661394182","title":"Arcutis Biotherapeutics' Zoryve Gets Health Canada Approval for Children With Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2661394182","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661394182?lang=en_us&edition=fundamental","pubTime":"2026-08-21 01:55","pubTimestamp":1787248555,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics'  Arcutis Canada unit said Thursday that Health Canada has approved Zoryve cream 0.05% to treat mild to moderate atopic dermatitis in children 2 to 5 years old.The approval is based on data from a phase 3 trial, which met its primary and key secondary endpoints, showing improvements in disease severity, with benefits observed as early as week 1, the company said.Trial results were well-tolerated through week 56, with treatment-emergent adverse events predominantly mild to moderate in severity, the company said.Price: 24.99, Change: -1.47, Percent Change: -5.56","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661393492","title":"Arcutis Canada: Przoryve Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2661393492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661393492?lang=en_us&edition=fundamental","pubTime":"2026-08-21 01:25","pubTimestamp":1787246746,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nFWN44H1HA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660475805","title":"Arcutis Biotherapeutics Director Howard G. Welgus Sells 4,730 Common Shares for $123,835.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2660475805","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660475805?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:57","pubTimestamp":1787173079,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics director Howard G. Welgus sells 4,730 common shares for $123,835.71Arcutis Biotherapeutics director Howard G. Welgus sold 4,730 common shares at USD 26.18 on Aug. 17.He exercis","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL33KSb2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Arcutis Biotherapeutics Director Howard G. Welgus Sells 4,730 Common Shares for $123,835.71","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659196367","title":"Arcutis EVP, Chief Medical Officer Patrick Burnett Disposes of USD 392,075.19 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659196367","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659196367?lang=en_us&edition=fundamental","pubTime":"2026-08-14 08:07","pubTimestamp":1786666042,"startTime":"0","endTime":"0","summary":"Arcutis EVP, Chief Medical Officer Patrick Burnett disposes of USD 392,075.19 in common sharesArcutis Biotherapeutics EVP, Chief Medical Officer Patrick Burnett exercised stock options on Aug. 11-12, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL34Cfjw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Arcutis EVP, Chief Medical Officer Patrick Burnett Disposes of USD 392,075.19 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659014166","title":"Arcutis Targets Real-World Itch Relief Data With New Phase 4 Roflumilast Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2659014166","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659014166?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:31","pubTimestamp":1786638710,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc ($ARQT) announced an update on their ongoing clinical study. Arcutis Backs New Itch Study in Atopic Dermatitis. This Ph...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arcutis-targets-real-world-itch-relief-data-with-new-phase-4-roflumilast-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arcutis-targets-real-world-itch-relief-data-with-new-phase-4-roflumilast-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658013944","title":"Arcutis Biotherapeutics Earnings Call Highlights Growth Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2658013944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658013944?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:28","pubTimestamp":1786494518,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc (($ARQT)) has held its Q2 earnings call. Read on for the main highlights of the call. Arcutis Biotherapeutics’ latest e...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arcutis-biotherapeutics-earnings-call-highlights-growth-momentum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arcutis-biotherapeutics-earnings-call-highlights-growth-momentum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DECU","PMDE","FEBU","ARQT","RGLO","VGFPF","GXDW","JOYT","VOTE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945916","title":"Arcutis Biotherapeutics Rilis Transkrip Paparan Kinerja Kuartal II 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945916","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945916?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:48","pubTimestamp":1786481339,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics rilis transkrip paparan kinerja kuartal II 2026Arcutis Biotherapeutics memaparkan hasil kinerja kuartal II 2026 pada earnings call 5 Agustus 2026, dihadiri CEO Frank Watanabe, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL1QWpkB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993809","title":"Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993809","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993809?lang=en_us&edition=fundamental","pubTime":"2026-08-11 16:10","pubTimestamp":1786435807,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN). Arcutis ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arcutis-biotherapeutics-arqt-and-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arcutis-biotherapeutics-arqt-and-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","ARQT","BHVN","HCSG","BK4137","XBI","LU1093756325.SGD","LU0128526141.USD","BK4139","LABU","LU0029874061.USD","BK4588","BK4581","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670494","title":"Arcutis Biotherapeutics (ARQT) Could Be 31% Undervalued Following Profit And Higher Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670494","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658670494?lang=en_us&edition=fundamental","pubTime":"2026-08-10 00:26","pubTimestamp":1786292804,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics (ARQT) is back on investor radars after second quarter 2026 results showed revenue of $129.86 million, net income of $15.01 million, and raised full year net product sales guidance.\nSee our latest analysis for Arcutis Biotherapeutics.\nThe latest results and raised full year guidance have come alongside a 19.07% 3 month share price return and a 71.23% 1 year total shareholder return. However, shorter term share price returns over the past month and year to date have...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-could-be-31-undervalued-followi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-could-be-31-undervalued-followi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TSPA","CDIG","ARQT","TACU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657739625","title":"Arcutis Biotherapeutics Grants 143,500 RSUs, 37,000 Stock Options to New Hires Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2657739625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657739625?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:00","pubTimestamp":1786132819,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics grants 143,500 RSUs, 37,000 stock options to new hires under inducement planArcutis Biotherapeutics granted 143,500 restricted stock units, with 37,000 stock options, to 24 new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL9LwtWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4139","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","ARQT","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BN0W2W23.USD","BK4585","LU0314104364.USD","SG9999014039.USD","BK4112","LU2210150020.SGD","LU2095319765.USD","BK4588","BCDF","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcutis.com;investors.arcutis.com","stockEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":-0.1181},{"period":"3month","weight":0.1258},{"period":"6month","weight":-0.0042},{"period":"1year","weight":0.4744},{"period":"ytd","weight":-0.177}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.076618},{"month":2,"riseRate":0.857143,"avgChangeRate":0.210567},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.041444},{"month":4,"riseRate":0.428571,"avgChangeRate":0.034314},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.100595},{"month":6,"riseRate":0.857143,"avgChangeRate":0.090855},{"month":7,"riseRate":0.714286,"avgChangeRate":0.024031},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.03181},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.043642},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.153349},{"month":11,"riseRate":0.5,"avgChangeRate":0.146122},{"month":12,"riseRate":0.666667,"avgChangeRate":0.153171}],"exchange":"NASDAQ","name":"Arcutis Biotherapeutics Inc.","nameEN":"Arcutis Biotherapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcutis Biotherapeutics Inc.(ARQT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcutis Biotherapeutics Inc.,ARQT,Arcutis Biotherapeutics Inc.股票,Arcutis Biotherapeutics Inc.股票老虎,Arcutis Biotherapeutics Inc.股票老虎国际,Arcutis Biotherapeutics Inc.行情,Arcutis Biotherapeutics Inc.股票行情,Arcutis Biotherapeutics Inc.股价,Arcutis Biotherapeutics Inc.股市,Arcutis Biotherapeutics Inc.股票价格,Arcutis Biotherapeutics Inc.股票交易,Arcutis Biotherapeutics Inc.股票购买,Arcutis Biotherapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcutis Biotherapeutics Inc.(ARQT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction